Article
Comparison of the class-1 outer membrane protein from B:15:P1.16 Neisseria meningitidis strains isolated from patients previously immunized with a serogroup B outer membrane protein vaccine in Norway.
Microbial pathogenesis - 1 Dec 1994
Brooks J L, Rosenqvist E, Bjune G, Lambden P R, Heckels J E
Abstract excerpt
A previous report of a large, double blind, efficacy trial of an experimental Group B meningococcal outer membrane protein vaccine carried out in Norwegian Teenagers, showed a protection rate of 57%. Previous studies had demonstrated the occurrence of mutations in the class-1 outer membrane protein which alter its immunological properties. The occurrence of new mutations might compromise the efficacy of a vaccine...
Topics
- Adolescent
- Amino Acid Sequence
- Bacterial Capsules
- Bacterial Vaccines
- DNA, Bacterial
- Female
- Gene Expression Regulation, Bacterial
- Humans
- Immunotherapy, Active
- Male